Intra-arterial therapies for metastatic colorectal cancer

Seminars in Interventional Radiology

Volumn 30, Issue 1, 2013, Pages 12-20

  Wang, David S ^a   Louie, John D ^a   Sze, Daniel Y ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

colorectal cancer; drug eluting beads; irinotecan; liver metastases; radioembolization

Indexed keywords

EID: 84874351924     PISSN: 07399529     EISSN: 10988963     Source Type: Journal    
DOI: 10.1055/s-0033-1333649     Document Type: Article

References (66)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin: 2011; 61 2 69 90
2. Surveillance Research Program, National Cancer Institute SEER stat fact sheets: Colon and rectum. Available at: http://seer.cancer.gov/statfacts/html/ colorect.html. Accessed August 20, 2012
3. Weiss L., Grundmann E., Torhorst J., et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol: 1986; 150 3 195 203
4. Choti M. A. Surgical resection of hepatic metastases. In: Geschwind J. F., Soulen M. C., eds. Interventional Oncology: Principles and Practice. New York, NY Cambridge University Press: 2008; 243 248
5. Sasson A. R., Sigurdson E. R. Surgical treatment of liver metastases. Semin Oncol: 2002; 29 2 107 118
6. Ma W. W., Messersmith W. A. Medical management of colorectal liver metastasis. In: Geschwind J. F., Soulen M. C., eds. Interventional Oncology: Principles and Practice. New York, NY Cambridge University Press: 2008; 222 242
7. Köhne C. H., Lenz H. J. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist: 2009; 14 5 478 488
8. Breedis C., Young G. The blood supply of neoplasms in the liver. Am J Pathol: 1954; 30 5 969 977
9. de Baere T., Deschamps F. Arterial therapies of colorectal cancer metastases to the liver. Abdom Imaging: 2011; 36 6 661 670
10. Wasan H., Kennedy A., Coldwell D., Sangro B., Salem R. Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases. Am J Clin Oncol: 2012; 35 3 293 301
11. Salem R., Thurston K. G. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol: 2006; 17 10 1571 1593
12. Nicolay N. H., Berry D. P., Sharma R. A. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol: 2009; 6 12 687 697
13. Deleporte A., Flamen P., Hendlisz A. State of the art: radiolabeled microspheres treatment for liver malignancies. Expert Opin Pharmacother: 2010; 11 4 579 586
14. Vente M. A., Wondergem M., van der Tweel I., et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol: 2009; 19 4 951 959
15. Gulec S. A., Pennington K., Wheeler J., et al. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (Chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial. Am J Clin Oncol: 2012;; June 14 (Epub ahead of print)
16. Sharma R. A., Van Hazel G. A., Morgan B., et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol: 2007; 25 9 1099 1106
17. Van Hazel G., Blackwell A., Anderson J., et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol: 2004; 88 2 78 85
18. Kosmider S., Tan T. H., Yip D., Dowling R., Lichtenstein M., Gibbs P. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. J Vasc Interv Radiol: 2011; 22 6 780 786
19. van Hazel G. A., Pavlakis N., Goldstein D., et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol: 2009; 27 25 4089 4095
20. Lim L., Gibbs P., Yip D., et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer: 2005; 5 132
21. Cosimelli M., Golfieri R., Cagol P. P., et al. Italian Society of Locoregional Therapies in Oncology (SITILO) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer: 2010; 103 3 324 331
22. Kennedy A. S., Coldwell D., Nutting C., et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys: 2006; 65 2 412 425
23. Bester L., Meteling B., Pocock N., et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol: 2012; 23 1 96 105
24. Cianni R., Urigo C., Notarianni E., et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol: 2009; 32 6 1179 1186
25. Jakobs T. F., Hoffmann R. T., Dehm K., et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol: 2008; 19 8 1187 1195
26. Nace G. W., Steel J. L., Amesur N., et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol: 2011; 2011 571261
27. Seidensticker R., Denecke T., Kraus P., et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol: 2012; 35 5 1066 1073
28. Hendlisz A., Van den Eynde M., Peeters M., et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol: 2010; 28 23 3687 3694
29. Lewandowski R. J., Thurston K. G., Goin J. E., et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol: 2005; 16 12 1641 1651
30. Aliberti C., Tilli M., Benea G., Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res: 2006; 26 5B 3793 3795
31. ®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res: 2011; 31 12 4581 4587
32. Martin R. C., Joshi J., Robbins K., et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol: 2011; 18 1 192 198
33. Fiorentini G., Aliberti C., Tilli M., et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res: 2012; 32 4 1387 1395
34. Martin R. C., Howard J., Tomalty D., et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol: 2010; 33 5 960 966
35. Biocompatibles DEBIRI algorithm-colorectal metastases. Available at: http://www.biocompatibles.com/products/dcbead/technique-guidelines. Accessed August 15, 2012
36. Albert M., Kiefer M. V., Sun W., et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, Ethiodol, and polyvinyl alcohol. Cancer: 2011; 117 2 343 352
37. Vogl T. J., Gruber T., Balzer J. O., Eichler K., Hammerstingl R., Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology: 2009; 250 1 281 289
38. Tellez C., Benson A. B. III, Lyster M. T., et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer: 1998; 82 7 1250 1259
39. Sanz-Altamira P. M., Spence L. D., Huberman M. S., et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum: 1997; 40 7 770 775
40. Lang E. K., Brown C. L. Jr. Colorectal metastases to the liver: selective chemoembolization. Radiology: 1993; 189 2 417 422
41. Kingham T. P., D'Angelica M., Kemeny N. E. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol: 2010; 102 8 988 995
42. Arai Y., Takeuchi Y., Inaba Y., et al. Percutaneous catheter placement for hepatic arterial infusion chemotherapy. Tech Vasc Interv Radiol: 2007; 10 1 30 37
43. Ganeshan A., Upponi S., Hon L. Q., Warakaulle D., Uberoi R. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol: 2008; 19 5 847 851
44. Antoine R. A. Technical considerations in percutaneous hepatic perfusion-a multi-center experience. J Extra Corpor Technol: 2011; 43 1 30 33
45. Miao N., Pingpank J. F., Alexander H. R., Steinberg S. M., Beresneva T., Quezado Z. M. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol: 2008; 15 3 815 823
46. SIRTeX Medical. SIR-Spheres Yttrium-90 microspheres package insert, October 2011. Available at: http://www.sirtex.com/files/SSL-US-09.pdf. Accessed August 15, 2012
47. Nordion M. DS. TheraSphere Yttrium-90 microspheres package insert, US ed. Available at: http://www.nordion.com/therasphere/physicians-package-insert/ package-insert-us.pdf. Accessed August 15, 2012
48. Stanford Interventional Radiology Interventional Oncology- Radioembolization. Available at: http://www.youtube.com/watch?v=3WwSfGPQq9g. Accessed August 15, 2012
49. Oken M. M., Creech R. H., Tormey D. C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol: 1982; 5 6 649 655
50. Salem R., Thurston K. G. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol: 2006; 17 9 1425 1439
51. Murthy R., Brown D. B., Salem R., et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol: 2007; 18 4 553 561; quiz 562
52. Abdelmaksoud M. H., Louie J. D., Kothary N., et al. Consolidation of hepatic arterial inflow by embolization of variant hepatic arteries in preparation for yttrium-90 radioembolization. J Vasc Interv Radiol: 2011; 22 10 1364 1371, e1
53. Abdelmaksoud M. H., Louie J. D., Kothary N., et al. Embolization of parasitized extrahepatic arteries to reestablish intrahepatic arterial supply to tumors before yttrium-90 radioembolization. J Vasc Interv Radiol: 2011; 22 10 1355 1362
54. Hashimoto M., Heianna J., Tate E., Kurosawa R., Nishii T., Mayama I. The feasibility of retrograde catheterization of the right gastric artery via the left gastric artery. J Vasc Interv Radiol: 2001; 12 9 1103 1106
55. Louie J. D., Kothary N., Kuo W. T., et al. Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol: 2009; 20 5 606 613
56. Sze D. Y., Louie J. D., Iagaru A. H., Abdelmaksoud M., Goris M. L. Survival after radioembolization is predicted by dose distribution scintigraphy fusion imaging [abstract]. J Vasc Interv Radiol: 2010; 21 2 S10
57. Kennedy A., Nag S., Salem R., et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys: 2007; 68 1 13 23
58. Lam M. G., Nijsen F., Smits M., et al. Limitations of the BSA-based dose calculation for Yttrium-90 radioembolization [abstract]. J Vasc Interv Radiol: 2012; 23 3 S68
59. Leung T. W., Lau W. Y., Ho S. K., et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys: 1995; 33 4 919 924
60. Abdelmaksoud M., Chang D., Eclov N. C., et al. Safety of Y90 radioembolization in patients who have undergone previous external beam radiation therapy [abstract]. J Vasc Interv Radiol: 2011; 22 3 S87
61. Abdelmaksoud M. H., Hwang G. L., Louie J. D., et al. Development of new hepaticoenteric collateral pathways after hepatic arterial skeletonization in preparation for yttrium-90 radioembolization. J Vasc Interv Radiol: 2010; 21 9 1385 1395
62. Louie J. D., Wang E. A., Broadwell S., et al. First in man experience with the Surefire infusion system: a dedicated microcatheter system to eliminate reflux during embolotherapy [abstract]. J Vasc Interv Radiol: 2012; 23 3 S80
63. Ahmadzadehfar H., Muckle M., Sabet A., et al. The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects. Eur J Nucl Med Mol Imaging: 2011; 39 2 309 315
64. Ha B. Y., Ahmed A., Sze D. Y., et al. Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. Aliment Pharmacol Ther: 2007; 26 6 839 846
65. Tognolini A., Louie J. D., Hwang G. L., Hofmann L. V., Sze D. Y., Kothary N. Utility of C-arm CT in patients with hepatocellular carcinoma undergoing transhepatic arterial chemoembolization. J Vasc Interv Radiol: 2010; 21 3 339 347
66. Fiorentini G., Aliberti C., Benea G., et al. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology: 2008; 55 88 2077 2082